Brazilian Consensus on second-generation antipsychotics and metabolic disorders;Consenso Brasileiro sobre antipsicóticos de segunda geração e distúrbios metabólicos

Revista Brasileira de Psiquiatria

Volumn 30, Issue 1, 2008, Pages 77-85

  Elkis, Helio ^a   Gama, Clarissa ^b   Suplicy, Henrique ^c   Tambascia, Marcos ^d   Bressan, Rodrigo ^e   Lyra, Ruy ^d   Cavalcante, Saulo ^d   Minicucci, Walter ^d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c Associacao Brasileira para O Estudo da Obesidade e da Sindrome Metabolica (ABESO)

^d Sociedade Brasileira de Diabetes ^*

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antipsychotic agents; Cardiovascular diseases; Diabetes mellitus, type 2; Metabolic syndrome X; Schizophrenia

Indexed keywords

ACARBOSE; ARIPIPRAZOLE; CLOZAPINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; INSULIN; MEGLITINIDE; METFORMIN; NEUROLEPTIC AGENT; OLANZAPINE; RIMONABANT; RISPERIDONE; SIBUTRAMINE; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; ZIPRASIDONE;

BRAZIL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONSENSUS; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; HUMAN; INFORMATION RETRIEVAL; MEDICAL SPECIALIST; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PSYCHIATRIST; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SITTING; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BRAZIL; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; METABOLIC DISEASES; METABOLIC SYNDROME X; OBESITY; SCHIZOPHRENIA;

EID: 41949092106     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-44462008000100014     Document Type: Review

References (70)

1. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ. Força-tarefa da WFSBP para diretrizes para o tratamento biológico da esquizofrenia. Parte 1: Tratamento agudo e Parte 2: Tratamento de longo prazo. Rev Psiq Clin. 2006;33(Supl 1): 7-64.
2. Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Ereshefsky L, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Rush AJ, Saeed SA, Schooler NR, Shon SP, Stroup S, Tarin-Godoy B. The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2003 Update. J Clin Psychiatry. 2004;65(4):500-8.
3. American Psychiatric Association. Practice guideline for the treatment of patient with schizophrenia. 2nd edition. Am J Psychiatry., February 2004.
4. IPAP. International Pharmacological Algorithm Project. Available at: www.ipap.org
5. Chou JC-Y. Review and Update of the American Psychiatric Association Practice Guideline for Bipolar Disorder. Prim Psychiatry. 2004;11(9):73-84.
6. Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter TA, Sachs GS, Swann AC; Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66(7):870-86.
7. Colton CW, Manderscheid RW. Prev Chronic Dis [serial online] 2006 Apr [date cited]. Available at URL: http://www.cdc.gov/pcd/issues/2006/apr/05_0180. htm
8. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity (Consensus Statement). Diabetes Care. 2004;27(2):596-601.
9. Agency for Healthcare Research and Quality. Systems to rate the strength of scientific evidence. Evidence report/technology assessment; 47. AHRQ publication no.02-E015;2002. Available at: www.ahrq.gov/clinic/epcsums/ strengthsum.htm
10. World Health Organization. Preventing chronic diseases - a vital investment. Obesity newsletter. 2005;8(2):3-28.
11. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med. 1999;341(6):427-34.
12. Diretrizes para Cardiologistas sobre Excesso de Peso e Doença Cardiovascular dos Departamentos de Aterosclerose, Cardiologia Clínica e FUNCOR da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2002;78(Suppl 1):1-13.
13. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev. 1994;74(4):761-811.
14. Ford ES, Giles WH, Mokdad AH, Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care. 2004;27(10):2444-9.
15. McNeil AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, Ballantyne CM, Heiss G. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005;28(2):385-90.
16. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999;22(2):345-54.
17. L'Italien GJ, Ford I, Shepherd J. The metabolic syndrome is an independent predictor of cardiac events in WOSCOPS males. Presented at: 52nd Annual Meeting of the American College of Cardiology; March 30-April 2, 2003; Chicago, Ill.
18. McNeill AM, Rosamond WD, Girman CJ, Ballantyne CM. A new definition of the metabolic syndrome predicts incident coronary heart disease and stroke [abstract]. Circulation. 2002;106(Suppl II):765.
19. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709-16.
20. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without CRP as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108(4):414-9.
21. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM; San Antonio Heart Study. The metabolic syndrome as a predictor of type 2 diabetes. Diabetes Care. 2003;26(11):3153-9.
22. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004;109(1):42-6.
23. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Williams RJ. The impact of the metabolic syndrome and diabetes on mortality from coronary heart disease, cardiovascular disease and all causes in United States adults. Circulation. 2004;110(10):1239-44.
24. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K; ECODE Study Group. Prevalence of the metabolic syndrome and its relation to all cause and cardiovascular mortality in non-diabetic European men and women. Arch Int Med. 2004;164(10):1066-76.
25. Blonde L, Ray S, Carson W, L'Italien GJ. Metabolic Syndrome is an Important Predictor of Cardiovascular Disease and New onset Diabetes - A Systematic Review of the Literature. Pôster apresentado na 158a. Reunião Anual da Associação Psiquiátrica Americana, Atlanta, GA, maio de 2005.
26. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683-9.
27. Wild S, Roglic G, Green A, Sicree S, King H. Global Prevalence Of Diabetes - Estimates For The Year 2000 And Projections For 2030. Diabetes Care. 2004;27(5):1047-53.
28. World Health Organization: The World Health Report 2003. Geneva, World Health Organization, 2003.
29. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economics costs of diabetes in U.S. in 2002. Diabetes Care. 2003;26(3):917-32.
30. Wirshing D. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry. 2004;65(Suppl 18):13-26.
31. Leitão-Azevedo CL, Abreu MG, Guimaraes LR, Moreno D, Lobato MI, Gama CS, Belmonte-de-Abreu PS. Sobrepeso e obesidade em pacientes esquizofrênicos em uso de clozapina comparado com o uso de outros antipsicóticos. Rev Psiquiatr Rio Gd Sul. 2006;2:120-8.
32. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002;71(3):239-57.
33. Newman SC, Bland RC. Mor tality in a cohor t of patients with schizophrenia: a record linkage study. Can J Psychiatry. 1991;36(4):239-45.
34. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of Schizophrenia. Brit J Psychiatry. 2000;177:212-7.
35. Newcomer JW. Metabolic disturbances associated with antipsychotic use. J Clin Psychiatry. 2001;62(Suppl 27) :3-4.
36. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-96.
37. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin LJ. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60(4):215-20.
38. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, Lindenmayer JP, Manoukian SV, Banerji MA, Lebovitz HE, Hennekens CH. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65 Suppl 7:4-18; quiz 19-20.
39. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(Suppl 1):20-7.
40. Baptista T. Body weight gain induced by antipsychotic drug: mechanisms and management. Acta Psychiatr Scand. 1999;100(1):3-16.
41. Leitão-Azevedo CL, Guimaraes LR, Abreu MG, Gama CS, Lobato MI, Belmonte-de-Abreu PS. Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics. Rev Bras Psiquiatr. 2006;28(4):301-4.
42. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157(6):975-1.
43. National Heart, Lung, and Blood Institute Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res. 1998;6( Suppl 2):51S-209S.
44. Toalson P, Ahmed S, Hardy T, Kabinoff G. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry. 2004;6(4):152-8.
45. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation. J Clin Psychopharmacol. 2004;24(5 Suppl 1):S7-14.
46. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord. 2002;26(1):137-41.
47. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry. 2003;160(2):284-9.
48. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 2003;64(5):575-9.
49. Basu R, Brar JS, Chengappa KN, John V, Parepally H, Gershon S, Schlicht P, Kupfer DJ. The prevalence of the metabolic syndrome in patients with schizoaffective disorder - bipolar subtype. Bipolar Disord. 2004;6(4):314-8.
50. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49(11):753-60.
51. Kato MM, Currier MB, Gomez CM, Hall L, Gonzalez-Blanco M. Prevalence of metabolic syndrome in hispanic and non-hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry. 2004;6(2):74-7.
52. Meyer JM. Schizophrenia and the metabolic syndrome. Medscape Psychiatry & Mental Health 2005;8(1):2005 Medscape. Available at: http://www.medscape. com/viewarticle/506136
53. Enger C, Weatherby L, Reynolds R, Glasser D, Walker A. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis. 2004;192(1):19-27.
54. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23.
55. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32.
56. L'Italien GJ, Meyer J, Koro CE. The prevalence of metabolic syndrome among schizophrenia patients is double that of the general population. Presented at: Annual Meeting of the American Diabetes Association; June 3-8, San Diego, CA.
57. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Gemma L, Santi L, Bonadonna RC, Muggeo M. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med. 2004;21(1):52-8.
58. Guedes EP. Tratamento do Diabetes Mellitus tipo 2 na Síndrome Metabólica. In: Godoy-Matos AF, organizador. Síndrome Metabólica. São Paulo: Atheneu; 2006. p.177-86.
59. Mancini MC. Obesidade: da Etiologia ao Diagnóstico. In: Lyra R, Cavalcanti N, organizador. Diabetes Mellitus. Rio de Janeiro: Diagraphic Editora; 2006. p. 139-44.
60. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC. A double-blind, placebo-controlled trial of sibutramine forn olanzapine-associated weight gain. Am J Psychiatry. 2005;162(5):954-62.
61. Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, Zhang H, Hayden D, Freudenreich O, Cather C, Evins AE, Goff DC. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand. 2007;115(2):101-5.
62. Taflinski T, Chojnacka J. Sibutramine-associated psychotic episode. Am J Psychiatry. 2000;157(12):2057-8.
63. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002;106(25):3143-421.
64. Kraus RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW Jr, Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St Jeor S, Suttie J, Tribble DL, Bazzarre TL. Dietary Guidelines revision 2000. A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation. 2000;102(18):2884-299.
65. Santos RD. Tratamento das dislipidemias. In: Lopes AC, Martinez TL, organizadores. Dislipidemias da teoria à prática. São Paulo: Atheneu; 2004. p. 395-403.
66. Santos RD. III Diretrizes brasileiras sobre dislipidemias e diretriz de prevenção da aterosclerose do departamento de aterosclerose da sociedade brasileira de cardiologia. Arq Bras Cardiol. 2001;77(Supl III):1-48.
67. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Brit J Psychiatry Suppl. 2004;47:s64-6.
68. Haddad P. Antipsychotics and diabetes: review of non-prospective data. Brit J Psychiatry Suppl. 2004;47:s80-6.
69. Meltzer HY. Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden. Proc Natl Acad Sci U S A. 2007;104(9):3019-20.
70. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry. 2001;62(Suppl 23):45-66.